These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33350678)

  • 21. Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers.
    Mathers B; Abadi S; Davies JM; McIntyre C; Ho C
    J Oncol Pharm Pract; 2023 Sep; 29(6):1381-1386. PubMed ID: 36320173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine, Cisplatin, and Nab-Paclitaxel as a First-Line Therapy for Advanced Biliary Tract Cancers.
    Gedela S; Munot P; Vaidyanathan A; Joarder R; Chaugule D; Parulekar M; Nashikkar C; Ghadi A; Vadodaria D; Goel M; Patkar S; Mandavkar S; Ramaswamy A; Bhargava P; Srinivas S; Ostwal V
    J Gastrointest Cancer; 2024 Mar; 55(1):263-269. PubMed ID: 37368175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
    Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
    Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
    Valle JW; Vogel A; Denlinger CS; He AR; Bai LY; Orlova R; Van Cutsem E; Adeva J; Chen LT; Obermannova R; Ettrich TJ; Chen JS; Wasan H; Girvan AC; Zhang W; Liu J; Tang C; Ebert PJ; Aggarwal A; McNeely SC; Moser BA; Oliveira JM; Carlesi R; Walgren RA; Oh DY
    Lancet Oncol; 2021 Oct; 22(10):1468-1482. PubMed ID: 34592180
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
    Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
    Williams KJ; Picus J; Trinkhaus K; Fournier CC; Suresh R; James JS; Tan BR
    HPB (Oxford); 2010 Aug; 12(6):418-26. PubMed ID: 20662793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
    Taghizadeh H; Unseld M; Schmiderer A; Djanani A; Wilthoner K; Buchinger D; Prager GW
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):109-115. PubMed ID: 32556829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States.
    Sheka AC; Altman A; Marmor S; Hui JYC; Denbo JW; Ankeny JS; Jensen EH
    Surg Oncol; 2020 Sep; 34():298-303. PubMed ID: 32891346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment.
    Cosgrove DP; Reese ES; Fulcher NM; Bobiak SS; Lamy FX; Allignol A; Boyd M; Mahmoudpour SH
    Cancer Med; 2023 Feb; 12(4):4195-4205. PubMed ID: 36263922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database.
    Kim BW; Oh CM; Choi HY; Park JW; Cho H; Ki M
    Gut Liver; 2019 Jan; 13(1):104-113. PubMed ID: 29938462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
    Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
    Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Riechelmann RP; Townsley CA; Chin SN; Pond GR; Knox JJ
    Cancer; 2007 Sep; 110(6):1307-12. PubMed ID: 17628484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.